yourstate.us
21 U.S.C. § 351

Adulterated drugs and devices

United States · Title 21 — FOOD AND DRUGS · Status: effective

Get this as JSONEmbed this
Cite this
Citation
21 U.S.C. § 351, Adulterated drugs and devices, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/454223
Permanent ID
ys:prov:454223@1
SHA-256
20970e90af8c76c4451302f453818fece00cf1fce9f541c541d14f261c28d87b

The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.

Full text

A drug or device shall be deemed to be adulterated— If it purports to be or is represented as a drug the name of which is recognized in an official compendium, and its strength differs from, or its quality or purity falls below, the standard set forth in such compendium. Such determination as to strength, quality, or purity shall be made in accordance with the tests or methods of assay set forth in such compendium, except that whenever tests or methods of assay have not been prescribed in such compendium, or such tests or methods of assay as are prescribed are, in the judgment of the Secretary, insufficient for the making of such determination, the Secretary shall bring such fact to the attention of the appropriate body charged with the revision of such compendium, and if such body fails within a reasonable time to prescribe tests or methods of assay which, in the judgment of the Secretary, are sufficient for purposes of this paragraph, then the Secretary shall promulgate regulations prescribing appropriate tests or methods of assay in accordance with which such determination as to strength, quality, or purity shall be made. No drug defined in an official compendium shall be deemed to be adulterated under this paragraph because it differs from the standard of strength, quality, or purity therefor set forth in such compendium, if its difference in strength, quality, or purity from such standard is plainly stated on its label. Whenever a drug is recognized in both the United States Pharmacopoeia and the Homoeopathic Pharmacopoeia of the United States it shall be subject to the requirements of the United States Pharmacopoeia unless it is labeled and offered for sale as a homoeopathic drug, in which case it shall be subject to the provisions of the Homoeopathic Pharmacopoeia of the United States and not to those of the United States Pharmacopoeia. If it is not subject to the provisions of paragraph (b) of this section and its strength differs from, or its purity or quality falls below, that which it purports or is represented to possess. If it is a drug and any substance has been (1) mixed or packed therewith so as to reduce its quality or strength or (2) substituted wholly or in part therefor. If it is a class III device— In the case of a device subject to an order issued under subsection (b) of section 360e of this title, paragraph 1 (1) shall not apply with respect to such device during the period ending— If it is a banned device. If it is a device and the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with applicable requirements under section 360j(f)(1) of this title or an applicable condition prescribed by an order under section 360j(f)(2) of this title. If it is a device for which an exemption has been granted under section 360j(g) of this title for investigational use and the person who was granted such exemption or any investigator who uses such device under such exemption fails to comply with a requirement prescribed by or under such section. If it is a drug or device and it has been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator, or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection. For purposes of paragraph (a)(2)(B), the term “current good manufacturing practice” includes the implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials, materials used in the manufacturing of drugs, and finished drug products.

Legislative history

The public laws that enacted or amended this section. Tallies are for the whole bill as it passed each chamber — often an omnibus covering far more than this provision — not a vote on this section alone. The law that originally enacted this section predates the public laws loaded here, so only later amendments are listed.

  • Amended byPub. L. 94-295(S. 510)1976-05-28
    Medical Device Amendments of 1976
    House: no recorded tallySenate: no recorded tally
  • Amended byPub. L. 101-629(H.R. 3095)1990-11-28
    Safe Medical Devices Act of 1990
    House: no recorded tallySenate: no recorded tally
  • Amended byPub. L. 102-571(H.R. 6181)1992-10-29
    To amend the Federal Food, Drug, and Cosmetic Act to authorize human drug application, prescription drug establishment, and prescription drug product fees and for other purposes.
    House: no recorded tallySenate: no recorded tally
  • Amended byPub. L. 105-115(S. 830)1997-11-21
    Food and Drug Administration Modernization Act of 1997
    House: no recorded tallySenate: 98–2
  • Amended byPub. L. 112-144(S. 3187)2012-07-09
    Food and Drug Administration Safety and Innovation Act
    House: no recorded tallySenate: 96–1
  • Amended byPub. L. 115-52(H.R. 2430)2017-08-18
    FDA Reauthorization Act of 2017
    House: no recorded tallySenate: 94–1